Biosimilars

A patent for a rheumatoid arthritis drug was ruled invalid, but Johnson & Johnson plans to appeal the decision.

Top articles of the week on The American Journal of Pharmacy Benefits.

AbbVie alleges that Amgen is infringing on 61 patents with their biosimilar.

Biosimilar to rheumatoid arthritis and inflammatory bowel disease drug shows similar efficacy to brand name drug.

Biosimilar to rheumatoid arthritis and inflammatory bowel disease drug shows similar efficacy to brand name drug.

Top news of the day from across the health care landscape.

Top news from across the health care landscape.

Top news of the day from across the healthcare landscape.

Discrepancies between drug costs and reimbursement from payers grows.

AbbVie and Amgen are attempting to stop biosimilars from emerging through the use of new patents.

Sandoz announced efforts to create biosimilars for oncology and immunology branded drugs.

Sandoz to create biosimilars for 5 popular branded drugs.

The Academy of Managed Care Pharmacy is proud to announce the launch of the Biosimilars Resource Center, an unbiased, policy-neutral repository of educational resources and information on biosimilars for pharmacists, physicians, nurses and other health care providers.

Biosimilars show promise for treatment of treat autoimmune diseases and hematological cancers.

With the introduction of biosimilars in the United States, there are several significant issues that will challenge those involved in formulary committees and benefit plans, as well as prescribers and pharmacists.

To ensure patient access to newer, more affordable versions of biologic medicines, the Food and Drug Administration should avoid requiring a statement of biosimilarity on the product label, a group of leading pharmaceutical supply chain organizations stated in a letter submitted to the agency today

As new biosimilars enter the market, pharmacies should carefully consider infrastructure, resources, and strategies for successfully integrating the products into their portfolio of offerings.

Remicade treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

The FDA approved 700 generic drugs in 2015.

Several biologic drug manufacturers face biosimilar competition, but are financial markets pricing them appropriately?

The interests of payors, physicians, and patients must be addressed for biosimilars to offer cost savings.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Policy decisions will affect how much biosimilars improve patient access to advanced treatments.

Most read articles of the week on Specialty Pharmacy Times.

The Generic Pharmaceutical Association and its Biosimilars Council are pleased that the Food and Drug Administration (FDA) has issued its draft guidance on biosimilar labeling.

Access to biologics increased by as much as 100% after biosimilars became available.

Biosimilars face scrutiny before they can be indicated for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.